Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 157,957 | 27,230 | 26,460 | 29,378 | 28,231 |
| Gross Profit | 157,957 | 27,230 | 26,460 | 29,378 | 28,231 |
| Operating Expenses | 139,923 | 82,622 | 81,354 | 75,112 | 73,492 |
| Operating Income | 18,034 | -55,392 | -54,894 | -45,734 | -45,261 |
| Other Income | 3,293 | 3,678 | 1,769 | 2,643 | 1,342 |
| Pre-tax Income | 21,327 | -51,714 | -53,125 | -43,091 | -43,919 |
| Income Tax | 194 | 259 | 30 | 82 | 58 |
| Net Income Continuous | 21,133 | -51,973 | -53,155 | -43,173 | -43,977 |
| Net Income | $21,133 | $-51,973 | $-53,155 | $-43,173 | $-43,977 |
| EPS Basic Total Ops | 0.13 | -0.32 | -0.34 | -0.29 | -0.30 |
| EPS Basic Continuous Ops | 0.13 | -0.32 | -0.34 | -0.29 | -0.30 |
| EPS Diluted Total Ops | 0.12 | -0.32 | -0.34 | -0.29 | -0.30 |
| EPS Diluted Continuous Ops | 0.12 | -0.32 | -0.34 | -0.29 | -0.30 |
| EBITDA(a) | $60,705 | $-50,870 | $-50,244 | $-40,688 | $-40,159 |